NASDAQ · Biotechnology

PCVX (PCVX) Stock

$55.50 +1.54% NASDAQ: PCVX Healthcare

Valuation

MetricValue
Price$55.50
Market Cap$8.01B
P/E Ratio-7.28
P/B Ratio2.60
P/S Ratio0.00
EPS (TTM)$-5.63
52-Week High$65.00
52-Week Low$29.08
Dividend Yield—

Financials & Margins

MetricValue
ROE-30.55%
ROA-20.23%
ROCE-34.40%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.04
Current Ratio7.90

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-104.0M$-232.0M$-468.0M$-570.0M$-924.0M
Net Profit$-100.0M$-223.0M$-402.0M$-464.0M$-767.0M
EPS$-1.93$-3.44$-4.14$-3.80$-5.63
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$324.0M$1.0B$1.4B$3.5B$3.0B
Total Liabilities$40.0M$53.0M$167.0M$205.0M$360.0M
Cash$69.0M$835.0M$397.0M$388.0M$174.0M
Borrowings$17.0M$18.0M$29.0M$71.0M$229.0M

Latest News

Vaxcyte to Participate in Upcoming Investor Conferences GlobeNewswire · Jul 8, 2026 Vaxcyte Inc (PCVX) Is A Hidden Multibagger Stock To Buy Now Insider Monkey · Jul 3, 2026 Vaxcyte Insider Sold Shares Worth $1,338,270, According to a Recent SEC Filing MT Newswires · Jun 29, 2026 Vaxcyte (PCVX) Doses Its First Patient in a Trial for a Disease With No Existing Vaccine Insider Monkey · Jun 22, 2026 Vaxcyte Insider Sold Shares Worth $1,284,205, According to a Recent SEC Filing MT Newswires · Jun 22, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-121.0M$-171.0M$-297.0M$-453.0M$-656.0M
Investing Cash Flow$-219.0M$69.0M$-841.0M$-2.0B$424.0M
Financing Cash Flow$4.0M$5.0M$4.0M$13.0M$2.0M
Net Cash Flow$-316.0M$766.0M$-437.0M$-9.0M$-214.0M
Free Cash Flow$-128.0M$-176.0M$-365.0M$-475.0M$-669.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.11
EV / EBITDA-5.76
FCF Yield-8.58%
Quick Ratio7.18
Interest Coverage—
Return 1Y62.85%
Return 3Y19.57%
Return 5Y157.73%

Ownership

Insiders Held0.50%
Institutions Held113.92%
Institutions Float Held114.49%
Institutional HolderSharesReport Date
Janus Henderson Group PLC16,575,8752026-03-31
FMR, LLC16,492,8612026-03-31
T. Rowe Price Investment Management, Inc.12,126,0172026-03-31
RA Capital Management, L.P.11,474,5992026-03-31
Blackrock Inc.10,971,8162026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACLXArcellx, Inc. $115.07 +0.02% -28.27 $6.73B 0.00%
AKROAkero Therapeutics, Inc. $54.65 +0.00% -19.87 $4.50B 0.00%
ALKS $50.71 -3.84% 25.87 $8.45B 0.00%
ARWR $86.01 +1.61% -7397.00 $12.12B 0.00%
CRNX $83.81 -0.09% -8.57 $8.87B 0.00%

About PCVX

PCVX is led by CEO Grant E. Pickering, employs 507 people, headquartered in San Carlos, US, publicly traded since 2020.

PCVX stock trades at $55.50 with a market capitalization of $8.01B. The stock is valued at a price-to-earnings (P/E) ratio of -7.28, price-to-book of 2.60, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $29.08 and $65.00, and currently trades 14.6% below its 52-week high.

On profitability, PCVX generates a return on equity (ROE) of -30.55%, return on capital employed of -34.40%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides